JP7712994B2 - 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤 - Google Patents

疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤

Info

Publication number
JP7712994B2
JP7712994B2 JP2023186694A JP2023186694A JP7712994B2 JP 7712994 B2 JP7712994 B2 JP 7712994B2 JP 2023186694 A JP2023186694 A JP 2023186694A JP 2023186694 A JP2023186694 A JP 2023186694A JP 7712994 B2 JP7712994 B2 JP 7712994B2
Authority
JP
Japan
Prior art keywords
cancer
peak
clause
compound
theta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023186694A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024067008A (ja
JP2024067008A5 (enExample
Inventor
アンドリュー コーツ，デイビッド
ラケル ヒルデン，ロリ
クミネック，ジスレーヌ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Petra Pharma Corp
Original Assignee
Petra Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Petra Pharma Corp filed Critical Petra Pharma Corp
Publication of JP2024067008A publication Critical patent/JP2024067008A/ja
Publication of JP2024067008A5 publication Critical patent/JP2024067008A5/ja
Application granted granted Critical
Publication of JP7712994B2 publication Critical patent/JP7712994B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/03—Monoamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023186694A 2022-11-02 2023-10-31 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤 Active JP7712994B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263421636P 2022-11-02 2022-11-02
US63/421,636 2022-11-02
US202263423879P 2022-11-09 2022-11-09
US63/423,879 2022-11-09

Publications (3)

Publication Number Publication Date
JP2024067008A JP2024067008A (ja) 2024-05-16
JP2024067008A5 JP2024067008A5 (enExample) 2024-10-24
JP7712994B2 true JP7712994B2 (ja) 2025-07-24

Family

ID=88978500

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023186694A Active JP7712994B2 (ja) 2022-11-02 2023-10-31 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤

Country Status (8)

Country Link
EP (1) EP4612136A1 (enExample)
JP (1) JP7712994B2 (enExample)
KR (1) KR20250097960A (enExample)
CN (1) CN120476112A (enExample)
AU (1) AU2023373670A1 (enExample)
MX (1) MX2025005020A (enExample)
TW (1) TWI887826B (enExample)
WO (1) WO2024097205A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119874676A (zh) * 2023-10-25 2025-04-25 海创药业股份有限公司 一种pi3k抑制剂及其制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006500361A (ja) 2002-08-16 2006-01-05 キネイシア ピーティーワイ リミテッド ホスホイノシチド３−キナーゼβの阻害
WO2010049525A1 (en) 2008-10-31 2010-05-06 C-A-I-R Biosciences Gmbh Choline and tromethamine salt of licofelone
US20180298025A1 (en) 2017-03-03 2018-10-18 Gilead Sciences, Inc. Processes for preparing acc inhibitors and solid forms thereof
JP2021050230A (ja) 2012-11-05 2021-04-01 エモリー ユニバーシティー ７，８−ジヒドロキシフラボンおよび７，８−置換フラボン誘導体、組成物、およびそれらに関連する方法
WO2022235574A1 (en) 2021-05-03 2022-11-10 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA21528A1 (fr) * 1988-04-06 1989-12-31 Lipha Composants substituants du flavonoide, leurs sels, leurs manufactures et produits contenant ces matieres .
AR121719A1 (es) * 2020-04-03 2022-06-29 Petra Pharma Corp Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006500361A (ja) 2002-08-16 2006-01-05 キネイシア ピーティーワイ リミテッド ホスホイノシチド３−キナーゼβの阻害
WO2010049525A1 (en) 2008-10-31 2010-05-06 C-A-I-R Biosciences Gmbh Choline and tromethamine salt of licofelone
JP2021050230A (ja) 2012-11-05 2021-04-01 エモリー ユニバーシティー ７，８−ジヒドロキシフラボンおよび７，８−置換フラボン誘導体、組成物、およびそれらに関連する方法
US20180298025A1 (en) 2017-03-03 2018-10-18 Gilead Sciences, Inc. Processes for preparing acc inhibitors and solid forms thereof
WO2022235574A1 (en) 2021-05-03 2022-11-10 Petra Pharma Corporation Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of disease
JP7308369B2 (ja) 2021-05-03 2023-07-13 ペトラ・ファーマ・コーポレイション 疾患の治療のためのホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤

Also Published As

Publication number Publication date
JP2024067008A (ja) 2024-05-16
CN120476112A (zh) 2025-08-12
WO2024097205A1 (en) 2024-05-10
EP4612136A1 (en) 2025-09-10
TW202432100A (zh) 2024-08-16
TWI887826B (zh) 2025-06-21
MX2025005020A (es) 2025-08-01
AU2023373670A1 (en) 2025-05-15
KR20250097960A (ko) 2025-06-30

Similar Documents

Publication Publication Date Title
JP7383652B2 (ja) Ｂ－ｒａｆキナーゼのマレイン酸塩、結晶形、調整方法、及びその使用
CN106188138B (zh) 一种二氨基嘧啶化合物及包含该化合物的组合物
JP6457623B2 (ja) ２，４−二置換７Ｈ−ピロロ［２，３−ｄ］ピリミジン誘導体、その製造方法および医薬における使用
US9487529B2 (en) Macrocyclic compounds as ALK, FAK and JAK2 inhibitors
CN118005656B (zh) Kras g12c突变蛋白嘧啶并噻喃二酮类抑制剂的制备及其应用
CN115677702B (zh) 三并环化合物及其药物组合物和应用
AU2019209475A1 (en) Inhibitors of cyclin-dependent kinase 7 (CDK7)
JP2021527717A (ja) 選択的ｃｄｋ９阻害剤としての酒石酸塩及びその結晶形
CN116390728B (zh) 喹唑啉衍生物及其制备方法和用途
JP7712994B2 (ja) 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤
CN117143093A (zh) 一种蛋白降解剂及其制备方法和用途
JP2021531287A (ja) Ｍａｇｌ阻害剤としての複素環式スピロ化合物
CN115677730B (zh) 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途
TWI786303B (zh) 抑制ｃｄｋ4/6活性化合物的晶型及其應用
CN110407839B (zh) 含杂芳基酰胺结构的三唑并杂环类化合物的制备及应用
TWI863667B (zh) 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑
US20250282761A1 (en) Salt and crystal forms of an epidermal growth factor receptor inhibitor
JP7034430B2 (ja) 重水素化インドールアミン２，３－ジオキシゲナーゼ阻害剤及びその使用
WO2025231053A1 (en) Solid forms of 6-chloro-3-[(1r)-1-[3,6-dimethyl-2-(2-methylindazol-5-yl)-4-oxo-chromen-8-yl]ethoxy]pyridine-2-carboxamide
TWI907258B (zh) Kras g12c突變蛋白嘧啶並噻喃二酮類抑制劑的製備及其應用
HK40124018A (en) Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
WO2025026442A1 (zh) 稠环类化合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241016

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250711

R150 Certificate of patent or registration of utility model

Ref document number: 7712994

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150